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Summary
Primary systemic carnitine deficiency (SCD) is a rare he-
reditary disorder transmitted by an autosomal recessive
mode of inheritance. The disorder includes cardiomy-
opathy, muscle weakness, hypoketotic coma with hy-
poglycemia, and hyperammonemia. In this study, we
conducted a linkage analysis of a Japanese SCD family
with a proband—a 9-year-old girl—and 26 members.
The serum and urinary carnitine levels were determined
for all members. The entire genome was searched for
linkage to the gene locus for SCD, by use of a total of
∼300 polymorphic markers located ∼15–20 cM apart.
In the family, there were two significantly different phe-
notypes, in terms of serum free-carnitine levels: low se-
rum free-carnitine level ( mM; ) and29.5 5.0 n  14
normal serum free-carnitine level ( mM;46.8 6.2
). There was no correlation of urinary free-car-n  12
nitine levels with the low serum-level phenotype (pu-
tative heterozygote), but in normal phenotypes (wild
type) urinary levels decreased as the serum levels de-
creased; renal resorption of free carnitine appeared to
be complete in wild-type individuals, when the serum
free-carnitine level was !36 mM. Linkage analysis using
an autosomal dominant mode of inheritance of heter-
ozygosity revealed a tight linkage between the disease
allele and D5S436 on chromosome 5q, with a two-point
LOD score of 4.98 and a multipoint LOD score of 5.52.
The haplotype analysis revealed that the responsible ge-
netic locus lies between D5S658 and D5S434, which we
named the “SCD” locus. This region was syntenic with
the jvs locus, which is responsible for murine SCD. Phy-
logenic conversion of the SCD locus strongly suggests
involvement of a single gene, in human SCD.
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Introduction
Primary systemic carnitine deficiency (SCD; MIM
212140) is a rare hereditary disorder that is transmitted
by an autosomal recessive mode of inheritance (Roe and
Coates 1995). It is a specific disease characterized by
progressive cardiomyopathy, skeletal myopathy, hypo-
ketotic hypoglycemic encephalopathy, and hyperam-
monemia. Furthermore, SCD is emerging as one of the
causes of sudden infant death syndrome (Rinaldo et al.
1997).
The hallmark of SCD is low concentrations of car-
nitine in plasma and targeted tissues, with accumulation
of lipid deposits and renal leakage of carnitine. The clin-
ical symptoms are alleviated dramatically by oral ad-
ministration of L-carnitine (Tripp et al. 1981) but, if the
SCD is untreated, are precipitated into a crisis, with
Reye-like syndrome or cardiac arrest, by even a minor
episode of respiratory illness. The studies of carnitine
uptake in vitro support the concept that SCD is due to
a defect in the active transport of carnitine from extra-
cellular fluid into the cell, in selected tissues, such as
kidney, heart, muscle, and fibroblasts (Treem et al.
1988).
Mice with juvenile visceral steatosis (jvs) (Koizumi et
al. 1988) have been suggested as a murine disease model
for human SCD. In homozygous mice, the serum total-
and free-carnitine levels were significantly lower than
those in control mice. On the other hand, there was no
decrease in urinary excretion of carnitines (Kuwajima et
al. 1991). The linkage analysis located the responsible
locus, jvs, to chromosome 11 (Nikaido et al. 1995); the
putative syntenic region in the human genome is located
on the q arm of chromosome 5.
As yet, the molecular basis of human SCD has not
been explored. Linkage analysis would provide pivotal
information leading to the identification of the gene re-
sponsible for SCD. The linkage analysis, however, is con-
fronted with two major obstacles. First, in order to map
the responsible locus, a large number of families would
be required, owing to the mode of inheritance of an
autosomal recessive trait, unless heterozygotes could be
segregated by phenotype. Second, identification of het-
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erogeneity of the disease phenotype has been suspect in
human SCD (Roe and Coates 1995). One phenotype is
an early age-at-onset type with recurrent attacks of Reye-
like syndrome, with or without cardiomyopathy. An-
other is a late age-at-onset type with cardiomyopathy
and without any recurrent episodes of Reye-like
syndrome.
One solution to these difficulties is to conduct a link-
age analysis of the family of a proband, with a clear
clinical segregation of heterozygous subjects from the
wild types. This approach appears to be feasible, since
the parents of a proband who are heterozygous for the
defective gene have been reported to have impaired car-
nitine transport that is 40%–50% of normal (Tein et al.
1990).
In this article, we report the results of a linkage anal-
ysis of a family with SCD. The expected difficulties were
circumvented by the clear segregation of heterozygotes
from wild types. A single responsible gene locus was
assigned to 5q, which is in complete agreement with the
syntenic region of the murine model jvs locus.
Subjects and Methods
The Patient and Study Pedigree
A girl (the proband; subject 20, fig. 1), the first child
of unrelated parents, had complained intermittently of
easy fatigue, vomiting, and abdominal pain, from 7 years
of age. The proband was admitted to the Akita Univer-
sity Hospital when she was 8 years of age. She had
unexplained fever, weakness, irregular respiration, and
bradycardia and had lapsed into unconsciousness. She
was found to have hepatomegaly and muscle weakness.
The plasma or serum levels were as follows: ammonia
at 179 mg/dl, asparatate aminotransferase at 275 IU/liter,
alanine aminotransferase at 146 IU/liter, lactate dehy-
drogenase at 1,005 IU/liter, and creatine kinase at 1,261
IU/liter. Total- and free-carnitine levels in the serumwere
4.6 and 3.6 mM, respectively, with a relatively high total
urinary-carnitine concentration (225.7 mM). Dicarbox-
ylic aciduria in the urine was absent, as determined by
gas chromatography/mass spectrometry (GC/MS). A
standard laboratory blood panel was taken for the pro-
band, which included blood pH, blood gases, red blood
cell count, and blood glucose levels. Background elec-
troencephalogram activity revealed a pattern of predom-
inantly d waves and less v waves, at admission. Echo-
cardiograms showed left ventricular hypertrophy with
normal left ventricular systolic function. The clinical
symptoms gradually improved with intravenous glucose-
drip infusion and disappeared within a few days. How-
ever, the hyperammonemia and extremely low carnitine
concentrations in the serum were not alleviated by the
treatment. The carnitine uptake was assessed in vitro by
use of cultured skin fibroblasts from the proband and
her parents, as described elsewhere (Stanley et al. 1991).
The mean (SD) uptake velocity (V) at 5 mM of extra-
cellular carnitine was pmol/min/mg protein0.12 0.01
(triplicate determinations) for the proband, 0.64
pmol/min/mg protein (triplicate determinations) for0.01
the parents (subjects 12 and 13), and pmol/1.12 0.31
min/mg protein (triplicate determinations) for the nor-
mal subjects ( ). The Vmax of carnitine uptake forn  5
fibroblasts from the parents was 56% of that of the
normal subjects (triplicate determinations, 0.95
pmol/min/mg protein for the parents and0.26 1.70
pmol/min/mg protein for the normal subjects), but0.82
the Michaelis constants (Km’s) were comparable (tripli-
cate determinations, mM for the parents3.82 1.30
and mM for the normal subjects). In the3.42 1.63
patient, the renal plasma threshold for free-carnitine ex-
cretion and the tubular reabsorptive maximum, per 100
ml glomerular filtrate, for free carnitine were 17 nmol/
ml and 3.7 mmol/100 ml, respectively, which were lower
than the reported normal values nmol/ml and46 7.1
mmol/100 ml (Engel et al. 1981).7.2 0.44
This was the proband’s first episode of Reye-like syn-
drome. There was no family history of sudden infant
death syndrome, Reye syndrome, or unexplained neu-
ralgic, cardiac, or muscle disease. The proband’s two
siblings (subjects 21 and 22) have not had such episodes.
On the basis of these findings, we diagnosed the pro-
band as having SCD. Since the episode of illness, the
patient has been treated with L-carnitine, 100–150 mg/
kg/d taken orally, for 14 mo and has not suffered from
any subsequent attacks. Initially, her body weight and
height were below the first SD of the age-matched mean
levels; since treatment began, her height and weight have
been increasing and are now approaching average. Car-
diac hypertrophy and muscular weakness also have im-
proved significantly. Past medical-history interviews by
physicians of the other family members turned up no
reports of muscular weakness, cardiac symptoms, or
other related symptoms.
Serum- and Urinary-Carnitine Determination
Participants were requested to refrain from eating
meat at their most recent meal and to fast between the
evening meal and the interview time. Fasting blood and
urine samples were collected at the early morning in-
terviews. In addition to the first sample collection, blood
and urine samples were collected at two other times,
from selected members whose initial serum total- and
free-carnitine levels met the screening criteria. To set the
screening criteria, we determined serum carnitine levels
for 50 male and 50 female volunteers, whose ages were
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Figure 1 Haplotypes and recombinations in the study pedigree. The alleles at the microsatellite loci D5S428, D5S433, D5S471, D5S658,
D5S436, D5S434, D5S470, D5S487, D5S412, D5S422, D5S621, D5S423, and D5S429 are given for each individual. A question mark (?)
indicates that no data were available. Haplotypes were optimized by use of the GENEHUNTER software, and the affected chromosomes in
the grandparent generation are represented by blackened bars (subjects 1 and 5). A gray-shaded bar (subject 20) indicates that whether the
region is from an affected or a normal chromosome was undetermined. No attempt was made to show crossovers on the normal chromosome.
Circles denote females; squares denote males; the blackened circle denotes the proband; gray-shaded symbols denote heterozygotes; and the
symbol with a slash denotes a deceased member of the pedigree. To protect privacy, ages were abbreviated as follows: “!10 y” for those younger
than 10 years; “10s y” for teens; and “30s y” for those in their 30s, “40s y” for those in their 40s, and so on.
within the range of 1–75 years. These volunteers also
were requested to refrain from eating meat at their most
recent meal and to fast between the evening meal and
the blood collection.
Serum and urinary carnitine levels were determined
by an enzymatic cycling method using carnitine dehy-
drogenase (Takahashi et al. 1994). Serum was separated
from the whole blood by centrifugation on the day of
sample collection. Urine and serum were stored at
20C until assayed. Total-, acyl-, and free-carnitine
concentrations were standardized against creatinine con-
centrations in the urine.
Preparation of DNA and Marker Analysis
DNA also was isolated from the blood collected dur-
ing the interview. DNA was extracted by use of a DNA
isolation kit (DNA Purification System, Promega). A to-
tal of ∼300 polymorphic markers, located ∼15–20 cM
apart, were selected on the basis of their polymorphic-
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Table 1
Serum Carnitine Levels of 50 Males and 50 Females, for Setting of
the Heterogeneity Criteria
SEX
CONCENTRATION OF SERUM CARNITINEa
(mM)
Total Free Acyl
Male 61.0  6.9 51.3  5.6∗ 9.8  4.4
Female 59.6  5.9 48.4  6.10 11.8  4.2
a Determined by the enzymatic cycling method. Values are means
 SDs.
∗ , by ANOVA.P ! .05
information content, garnered primarily from the genetic
map from Ge´ne´thon and the National Institute of
Health–Center d’Etude du Polymorphism Humain.
High-resolution mapping was conducted for the area
covering the region syntenic with the mouse jvs gene
(Nikaido et al. 1995), by use of a total of 13 polymor-
phic dinucleotide-repeat markers from D5S428 to
D5S429. These markers covered the entire cytogenic re-
gion from 5q13.1. to 5q35.1. Three different fluorescent
dye–labeled primer pairs were prepared for visualization
of the PCR products. PCR was performed in a 15-ml
volume containing 50 ng of genomic template, 5.0 pmol
of each primer, 0.3 U of DNA polymerase (Taq Gold,
Takara), 300 mM of each dNTP, 1.5 ml of standard buf-
fer, and 1.5 mM ofMgCl2. Amplification was performed
in an MJ Research PTC-100 thermal cycler, at 95C for
10 min followed by 30 cycles at 94C or 89C for 15 s,
55C for 15 s, and 72C for 30 s and a final extension
at 72C for 10 min. The amplified DNA products were
analyzed by capillary electrophoresis on an ABI
PRISM310 genetic analyzer (Applied Biosystems).
Linkage Analysis
Two-point linkage analysis was performed on a per-
sonal computer by use of version 5.2 of the MLINK
program (Lathrop et al. 1984). Multipoint calculations
were performed by use of the LINKAGE package (La-
throp et al. 1984) and the GENEHUNTER software
(Kruglyak et al. 1996). The frequencies of the disease
allele and the normal allele were assumed to be .0001
and .9999, respectively, and the observed frequencies in
the family were assigned for the allele frequencies of
microsatellite markers. In the analysis, we assumed a
fully penetrant dominant phenotype, on the basis of het-
erozygosity. Since the linkage-analysis program GENE-
HUNTER limits the number of family members per ped-
igree, we separated the pedigree into three families, using
a method described elsewhere (Terwilliger and Ott
1994). Robustness with respect to separation of the fam-
ily was confirmed by testing different combinations of
separation. The calculated results were compared with
the results obtained by LINKMAP and were found to
be essentially the same. We thus present multipoint cal-
culations obtained by using the GENEHUNTER
program.
Informed Consent
Twenty-seven members of the pedigree participated in
the study and had signed informed-consent forms, in
accordance with Akita University Hospital guidelines.
We also obtained informed consent from the 50 male
and the 50 female blood donors used for the determi-
nation of standard levels of carnitine, for the setting of
the screening criteria. For individuals !14 years of age,
we obtained informed consent from their parents or
guardians.
Statistics
Serum carnitine values were presented as the means
 SDs. Statistical analyses, by ANOVA and regression
analysis, were performed on a Macintosh computer by
use of a statistical software package, STATIVIEW J4.5
(Abacus Concepts). A value of was consideredP ! .05
to be significant.
Results
Screening Heterozygotes
Serum carnitine levels in the population are shown in
table 1. Although serum free-carnitine levels in males
and females were statistically different, from a medical
viewpoint, these differences were negligible. We thus de-
termined common criteria for tentative assignment of
heterozygotes, for both genders. The screening levels for
heterozygotes were set as the . We did notmean 2 SD
use serum acylcarnitine for screening, because of a large
SD for a relatively small mean for this value. The ten-
tative screening criteria for putative heterozygotes were
defined as serum total-carnitine levels !46 mM and se-
rum free-carnitine levels !36 mM. Using these criteria,
we classified individuals as putative heterozygotes (low-
carnitine phenotype) or as having the wild-type phe-
notype (normal-carnitine phenotype), as shown in figure
1 and table 2. Note that the three repeat measures of
serum total- and free-carnitine levels in putative heter-
ozygotes never exceeded the screening level, except for
those of subject 7. On the other hand, the levels in all
the wild-type individuals were higher than the screening
levels. Subject 7 was undergoing hemodialysis and had
low serum free-carnitine levels but relatively high levels
of acylcarnitine. We collected blood samples from this
individual 1 d before hemodialysis.
Renal handling of carnitine also was evaluated in pu-
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Table 2
Segregation of Serum Total- and Free-Carnitine Levels, with Haplotypes at D5S658,
D5S436, and D5S434
SUBJECT SEX
CONCENTRATION OF SERUM CARNITINEa
(mM)
HAPLOYTYPEeTotalb Freec Acyld
Putative
heterozygote:
1 Female 42.1  3.3 33.9  1.4 8.2  1.9 532/254
5 Female 44.0  .2 33.2  1.8 10.8  1.6 622/244
7 Female 46.2  1.3 24.0  1.9 22.8  .5 622/244
9 Female 34.0  .9 27.1  .7 6.9  .2 622/244
10 Female 35.4  .3 30.7  .3 4.7  .0 532/232
12 Male 40.0  1.0 35.1  .2 4.9  .8 532/232
13 Female 36.6  2.4 28.1  3.3 8.5  .8 622/232
14 Female 40.9  1.6 33.7  1.9 7.2  .3 622/552
15 Female 27.4  1.5 18.7  1.3 8.7  .5 622/232
16 Female 27.3  2.4 22.4  2.2 5.4  .3 622/233
18 Female 33.2  2.4 28.9  2.8 4.4  .5 532/212
23 Male 43.5  .6 35.0  .4 8.5  .2 622/453
26 Female 36.4  .4 32.0  1.4 4.4  1.2 622/153
27 Female 34.0  2.3 30.7  1.2 3.3  1.2 223/153
Wild-type
phenotype:
2 Male 64.0 55.5 8.5 442/242
3 Female 68.7 56.9 11.8 632/252
4 Male 70.4 56.0 14.4 232/552
6 Female 50.1 40.7 9.4 332/233
8 Female 60.8 50.2 10.6 244/233
11 Female 53.2 40.7 12.5 25?/25?
17 Male 50.8 45.1 5.7 ?3?/?5?
19 Female 54.1 44.0 10.1 2?2/2?2
21 Female 59.5 44.5 15.0 ?3?/?3?
22 Female 64.5 41.2 23.3 232/232
24 Male 51.0 43.7 7.3 232/163
25 Female 50.4 42.9 7.5 233/331
a Serum total-, free-, and acylcarnitine levels were compared between two groups.
Values for putative heterozygotes are mean  SD.
b For putative heterozygotes, mean  37.2, SD 5.9. For wild phenotypes, mean 
58.1, SD 7.5. The former mean is significantly smaller than the latter ( , byP ! .01
ANOVA).
c For putative heterozygotes, mean  29.5, SD 5.0. For wild phenotypes, mean 
46.8, SD 6.2. The former mean is significantly smaller than the latter ( , byP ! .01
ANOVA).
d For putative heterozygotes, mean  7.7, SD 4.8. For wild phenotypes, mean 
11.3, SD 4.7. There is no significant difference between the two means.
e For the haplotype of each individual, refer to the pedigree shown in figure 1. An
underlined haplotype indicates an affected chromosomal segment. A question (?) mark
indicates that no data were available. The haplotype for the proband (subject 20) was
622/532.
tative heterozygotes and in those having wild-type phe-
notypes. Analysis revealed a unique relationship between
serum free-carnitine levels and urinary excretion of free
carnitine. Excretion of free carnitine (mmoles/g creati-
nine) increased linearly in wild types, whereas that of
putative heterozygotes showed a large variation irre-
spective of lowered serum carnitine levels (fig. 2A). In
the putative heterozygotes, free carnitine excreted in the
urine remained high even at serum levels !36 mM, but
in the wild types complete renal reabsorption was pre-
dicted to occur, by regression analysis, when serum con-
centrations were below this level. These data indicate
that there is an apparent phenotypic heterogeneity in
renal excretion of free carnitine, in relation to serum
levels in the pedigree: there was apparent renal leakage
in putative heterozygotes. In contrast, urinary acylcar-
nitine was found to be proportional to its serum levels
in both heterozygotes and wild types (fig. 2B).
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Figure 2 Relationship between serum and urinary free- and acyl-
carnitine levels in putative heterozygotes and wild-type subjects. Serum
and urinary free- and acylcarnitine levels were determined as the mean
of three determinations, for putative heterozygotes, whereas those for
wild types were determined once. Subject 7 is on hemodialysis and
was not included, since urine samples were not available. A, Serum
free-carnitine levels (in mM; X-axis) and urinary free-carnitine levels
(in mmol/g creatinine; Y-axis). The regression line for wild-type phe-
notypes was ( , ), whereas that forY  106.4 3.1X r  .740 P ! .05
heterozygotes was ( , ). B, SerumY  30.4 0.77X r  .152 P 1 .05
acylcarnitine levels (in mM; X-axis) and urinary acylcarnitine levels (in
mmol/g creatinine; Y-axis). The regression line for wild-type phenotypes
was ( , ), whereas that for heterozy-Y  17.4 5.9X r  .847 P ! .01
gotes was ( , ).Y  9.6 10.2X r  .803 P 1 .01
Table 3
Two-Point LOD Scores between SCD Locus and 13 Marker Loci
on 5q
MARKER
LOD SCORE AT RECOMBINATION
FRACTION (v) OF
Zmax vmax.00 .01 .03 .1 .2 .3
D5S428  2.99 1.68 .54 .17 .04 .04 .3
D5S433 .25 .25 .24 .22 .18 .14 .25 .0
D5S471  .51 .29 .82 .74 .48 .84 .13
D5S658  3.42 3.71 3.52 2.72 1.72 3.73 .04
D5S436 4.98 4.89 4.70 4.04 3.01 1.91 4.98 .0
D5S434 1.78 1.77 1.73 1.53 1.16 .7 1.78 .0
D5S470  1.65 .75 .08 .36 .36 .36 .3
D5S487 .24 .24 .24 .22 .18 .14 .24 .1
D5S412  3.85 2.37 .81 .10 .12 .12 .3
D5S422  8.42 5.6 2.64 1.17 .5 .5 .3
D5S621  1.91 1.01 .16 .17 .23 .23 .3
D5S423  8.66 5.47 2.31 .92 .37 .37 .3
D5S429  7.29 4.48 1.6 .31 .13 .13 .3
Linkage Analysis
These phenotypic characteristics suggested that the
phenotypic heterogeneity was inherited in an autosomal
dominant mode (fig. 1). We therefore assumed an au-
tosomal dominant mode of inheritance and a penetrance
of 99% for the linkage analysis. A search of the entire
genome revealed significant linkages with markers on
5q. The two-point LOD scores for the 13 microsatellite
markers are shown in table 3: The highest linkage was
observed between the disease allele and D5S436, with
a LOD score of 4.98. Multipoint linkage analysis re-
vealed large LOD scores between D5S658 and D5S434
(fig. 3), with a maximum LOD score (Zmax) of 5.52 at
D5S436.
Since hemodialysis is known to reduce plasma free
carnitine to subnormal levels (31–33 mM) and is known
to elevate plasma acylcarnitine in wild-type patients
(Golper et al. 1990), we also conducted linkage analysis
after excluding a patient (individual 7) who was under-
going hemodialysis. Exclusion of this individual de-
creased two-point and multipoint LOD scores to 4.67
and 5.22, respectively, but did not change the peak po-
sition at D5S436, with minor changes of other values
(data not shown).
The haplotype analysis of the affected chromosome
helped to determine the location of the gene by revealing
crossovers between the disease allele and the markers
(fig. 1). In subject 27, double crossovers between the
disease allele and D5S658 and D5S434 had occurred.
Thus, on the basis of haplotype analysis, the gene re-
sponsible for SCD lies at D5S436, within a region be-
tween D5S658 and D5S434.
Finally, we confirmed that serum total- and free-car-
nitine levels in heterozygous and wild-type subjects seg-
regated clearly with haplotypes at D5S658, D5S436,
and D5S434 (table 2). All subjects whose serum free-
carnitine levels were !36 mM shared one of two affected
chromosomal segments with the proband, whereas none
of the wild types shared these characteristics. This pat-
tern of segregation is in complete accordance with the
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Figure 3 Fourteen-point linkage analysis between SCD locus
and 13 marker microsatellite loci. Locus D5S428 was selected as a
starting point for the map. The Zmax and corresponding map location
were 5.52 and 66.1 cM, respectively. The centromere is located to the
left of the graph and is not shown.
presence or the absence of the defective gene, in this
region.
Discussion
The gene for primary SCD in humans was assigned
successfully to the long arm of chromosome 5 (5q31.1-
32), by linkage analysis of a single pedigree of an affected
family living in Japan. This is the first report on the
location of the genetic locus for human SCD. Our results
suggest that the carnitine-transporter gene lies on chro-
mosome 5q in humans. We would like to name this locus
“SCD.”
The haplotype analysis of the pedigree demonstrated
that there were no crossovers in a region flanking
D5S658 and D5S434, except in subject 27. Haplotype
analysis of subject 27 indicated that D5S436, located at
5q31.1, was the closest microsatellite marker. The in-
heritance of these marker alleles is completely consistent
with the phenotypes based on serum free-carnitine con-
centration and urinary excretion, autosomal dominant
mode of inheritance, and full penetrance. Furthermore,
it is quite interesting that the human assignment of SCD
is in complete agreement with a region syntenic with the
mouse jvs locus (Nikaido et al. 1995). The candidate
gene, which codes for a carnitine transporter, is ex-
pressed in different tissues (heart, muscle, kidney, and
fibroblasts) that play critical roles in SCD. The evidence
that the genetic defect for SCD appears to be the same
in evolutionarily distant mammals, such as humans and
mice, not only implies that the common mechanism is
phylogenetically conserved but also suggests that a single
gene is involved in SCD in both species.
Heterogeneity as determined by clinical phenotypes
often has been found to be suspect (Garavaglia et al.
1991; Roe and Coates 1995). The proband in this study
was classified as a case of late age at onset, judging from
her age at the first episode, but also could be classified
as a case of early age at onset, from the viewpoint of
symptomology. The age at onset easily may be affected
by various factors, such as incidences of respiratory in-
fections. Likewise, variation of symptoms also may be
modified by the maturity of physiological reservoir ca-
pacities against stress. At present, we assume a single
locus for SCD, despite apparent variations in clinically
diagnosed onset.
In conclusion, this study gave definitive evidence for
the genetic basis of SCD. Positional cloning of the car-
nitine-transporter gene will shed light on its physiolog-
ical role, as well as on the molecular mechanisms of the
disease. More importantly, the results of this study will
enable physicians to conduct genetic counseling and het-
erozygote screening of families that have a history sug-
gestive of SCD, a disease that is curable but that is often
overlooked and, therefore, fatal.
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